Skip to main content

Table 2 Progression-free survival results for patient characteristics and biomarkers

From: The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study

  N No.
Events
Median
Years
HR 95 % CI
for HR
HR
p-value
Race
 Non-White 9 9 1.77    
 White 57 57 1.93 1.20 (0.57, 2.54) 0.64
Gleason score
 5–7 13 13 3.59    
 8–10 51 51 1.60 1.77 (0.94, 3.34) 0.08
Performance Status
 0 31 31 1.97    
 1–2 35 35 1.70 1.20 (0.74, 1.96) 0.46
Metastatic Volume
 Low 31 31 3.53    
 High 35 35 1.27 2.93 (1.70, 5.05) <0.001
Treatment
 ADT 34 34 1.60    
 ADT + Chemo 31 31 2.29 0.99 (0.60, 1.61) 0.95
Diabetes
 No 62 62 1.93    
 Yes 4 4 0.92 2.28 (0.80, 6.45) 0.12
Age 66 66 1.77 0.99 (0.96, 1.02) 0.67
PSA (ln) 66 66 1.77 1.00 (0.99, 1.01) 0.65
Insulin (ln) 66 66 1.77 0.81 (0.67, 0.98) 0.03
RANK (ln) 66 66 1.77 0.82 (0.60, 1.12) 0.22
IGFBP3 (ln) 66 66 1.77 0.89 (0.52, 1.51) 0.66
IGFBP1 (ln) 66 66 1.77 1.05 (0.87, 1.27) 0.59
IGF I 66 66 1.77 0.85 (0.42, 1.74) 0.66
IGF II 66 66 1.77 0.80 (0.27, 2.42) 0.70
HGF (ln) 66 66 1.77 1.63 (1.06, 2.51) 0.03
OPN 66 66 1.77 1.56 (1.13, 2.15) 0.01
C-peptide (ln) 66 66 1.77 0.62 (0.39, 1.00) 0.05
PD1 (ln) 66 66 1.77 0.82 (0.53, 1.25) 0.35
IL6 (ln) 66 66 1.77 1.26 (0.91, 1.75) 0.17
OPG (ln) 66 66 1.77 0.97 (0.84, 1.11) 0.63
  1. PSA prostate specific antigen, RANK Receptor Activator of Nuclear Factor k B, IGFBP insulin-like growth factor binding protein, IGF insulin-like growth factor, HGF hepatocyte growth factor, OPN osteopontin, PD1 Programmed cell death protein 1, IL6 interleukin-6, OPG Osteoprotegerin
  2. For continuous measures, the HR is based on a one unit difference in the measurement